Sensitive Analyzer Detects Blood Biomarker for Traumatic Brain Injury
By LabMedica International staff writers Posted on 18 Aug 2015 |

Image: The Single Molecule Array (Simoa) HD-1 Analyzer (Photo courtesy of Quanterix Corporation).
Traumatic brain injury (TBI) is recognized as the signature injury in military personnel deployed for combat operations, and combat injuries and injuries in non-deployed settings have resulted in more than 300,000 TBI cases, with many experiencing multiple TBIs.
Tau is a microtubule-associated protein that functions as a structural element in the axonal cytoskeleton and elevations of tau concentration are an indication of axonal injury and are observed in the cerebral spinal fluid and peripheral blood of patients with severe TBI, professional boxers, and concussed athletes.
Scientists at the National Institute of Nursing Research, (NINR; Bethesda, MD, USA) and their colleagues carried out an observational assessment from September 2012 to August 2014 on 70 military patients with self-reported TBI and compared their tau concentrations in blood plasma to a control group consisting of 28 subjects. Non-fasting blood samples were collected into plastic dipotassium EDTA tubes, placed on ice, and centrifuged at 2,000 × g for 15 minutes at 4 °C, and plasma was aliquoted.
Tau concentrations in plasma samples were measured with a digital array technology (Quanterix Corporation; Lexington, MA, USA), which uses a single-molecule enzyme-linked immunoarray (Simoa) method. The Simoa Human Total Tau assay uses a combination of a monoclonal capture antibody that reacts with a linear epitope in the mid-region of all tau isoforms, and a detection antibody that reacts with a linear epitope in the N-terminus of total tau. The limit of detection for this assay is 0.012 pg/mL.
A significantly elevated concentration of total tau with a mean of 1.13 ± 0.78 pg/mL was found in the self-reported TBI group compared with the control group whose mean was 0.63 ± 0.48 pg/mL. Within the self-reported TBI cases, plasma total tau concentrations were significantly associated with having a medical record of TBI compared with self-reported TBI only. The severity of total post concussive symptoms correlated with total tau concentrations in the self-reported TBI group. They also found that participants with three or more deployment-related TBIs had significantly higher levels of tau compared with participants who had fewer TBIs.
The authors concluded that increases in total tau concentration in the peripheral blood in military personnel with multiple TBIs and chronic post concussive disorder (PCD) symptoms suggest that tau accumulations may contribute to chronic neurological symptoms following TBI. E. Kevin Hrusovsky, PhD, CEO of Quanterix Corporation, said, “This is one of the many studies in which Simoa is being used to further understand and quantify the long term effects of TBI and we are pleased to be working with NINR to continue our mission to understand what is going on in the human body and, in turn, improve the quality of care.” The study was published on August 3, 2015, in the journal JAMA Neurology.
Related Links:
National Institute of Nursing Research
Quanterix Corporation
Tau is a microtubule-associated protein that functions as a structural element in the axonal cytoskeleton and elevations of tau concentration are an indication of axonal injury and are observed in the cerebral spinal fluid and peripheral blood of patients with severe TBI, professional boxers, and concussed athletes.
Scientists at the National Institute of Nursing Research, (NINR; Bethesda, MD, USA) and their colleagues carried out an observational assessment from September 2012 to August 2014 on 70 military patients with self-reported TBI and compared their tau concentrations in blood plasma to a control group consisting of 28 subjects. Non-fasting blood samples were collected into plastic dipotassium EDTA tubes, placed on ice, and centrifuged at 2,000 × g for 15 minutes at 4 °C, and plasma was aliquoted.
Tau concentrations in plasma samples were measured with a digital array technology (Quanterix Corporation; Lexington, MA, USA), which uses a single-molecule enzyme-linked immunoarray (Simoa) method. The Simoa Human Total Tau assay uses a combination of a monoclonal capture antibody that reacts with a linear epitope in the mid-region of all tau isoforms, and a detection antibody that reacts with a linear epitope in the N-terminus of total tau. The limit of detection for this assay is 0.012 pg/mL.
A significantly elevated concentration of total tau with a mean of 1.13 ± 0.78 pg/mL was found in the self-reported TBI group compared with the control group whose mean was 0.63 ± 0.48 pg/mL. Within the self-reported TBI cases, plasma total tau concentrations were significantly associated with having a medical record of TBI compared with self-reported TBI only. The severity of total post concussive symptoms correlated with total tau concentrations in the self-reported TBI group. They also found that participants with three or more deployment-related TBIs had significantly higher levels of tau compared with participants who had fewer TBIs.
The authors concluded that increases in total tau concentration in the peripheral blood in military personnel with multiple TBIs and chronic post concussive disorder (PCD) symptoms suggest that tau accumulations may contribute to chronic neurological symptoms following TBI. E. Kevin Hrusovsky, PhD, CEO of Quanterix Corporation, said, “This is one of the many studies in which Simoa is being used to further understand and quantify the long term effects of TBI and we are pleased to be working with NINR to continue our mission to understand what is going on in the human body and, in turn, improve the quality of care.” The study was published on August 3, 2015, in the journal JAMA Neurology.
Related Links:
National Institute of Nursing Research
Quanterix Corporation
Latest Clinical Chem. News
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
- AI Model Detects Cancer at Lightning Speed through Sugar Analyses
- First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring
- New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
Channels
Molecular Diagnostics
view channel
RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms
Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more
First Of Its Kind Test Uses microRNAs to Predict Toxicity from Cancer Therapy
Many men with early-stage prostate cancer receive stereotactic body radiotherapy (SBRT), a highly precise form of radiation treatment that is completed in just five sessions. Compared to traditional radiation,... Read more
Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
Anti-myelin-associated glycoprotein (MAG) antibodies serve as markers for an autoimmune demyelinating disorder that affects the peripheral nervous system, leading to sensory impairment. Anti-MAG-IgM antibodies... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Deliver Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
Myasthenia gravis, an autoimmune disease, leads to muscle weakness that can affect a range of muscles, including those needed for basic actions like blinking, smiling, or moving. Researchers have long... Read more
AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
Lung adenocarcinoma, the most common form of non-small cell lung cancer (NSCLC), typically adopts one of six distinct growth patterns, often combining multiple patterns within a single tumor.... Read moreTechnology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more